Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment

Pan Afr Med J. 2019 Nov 1:34:125. doi: 10.11604/pamj.2019.34.125.19421. eCollection 2019.

Abstract

Squamous cell carcinoma of the prostate is rare and represents 0.5% to 1% of prostatic carcinomas. Transformation of prostatic adenocarcinoma into squamous cell carcinoma after LH-RH agonist intake has been reported in only 8 cases in the literature. To our knowledge, our case is the second pure squamous cell carcinoma observed after hormonotherapy and radiotherapy. We reported a case of a patient with prostatic adenocarcinoma treated by radical prostatectomy followed by radiotherapy. Eleven years later, he had a vesical recurrence of prostatic adenocarcinoma. Our patient had an endoscopic resection followed by injections of Triptorelin. Six months later, he developed a local recurrence of a squamous cell carcinoma.

Keywords: Prostate; hormonotherapy; squamous cell carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / pathology*
  • Adenocarcinoma / therapy
  • Aged
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Carcinoma, Squamous Cell / pathology*
  • Carcinoma, Squamous Cell / therapy
  • Combined Modality Therapy
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Male
  • Neoplasm Recurrence, Local
  • Prostatectomy
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy
  • Triptorelin Pamoate / administration & dosage

Substances

  • Antineoplastic Agents, Hormonal
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone